

REGISTERED POST

Luxembourg, 31 January 2025

NOTICE TO SHAREHOLDERS

Dear Shareholders,

The Board of Directors wishes to inform you of the following:

1) Prohibition of double-dipping

Shareholders are hereby informed that if a sub-fund invests in the units of other UCITS and/or other UCIs which are managed, directly or by delegation, by the Management Company or by any other company with which the Management Company is associated as part of a co-management or co-control agreement or by means of a significant direct or indirect shareholding, the Management Company or the other company may not charge subscription or redemption fees for the sub-fund's investment in the units of other UCITS and/or other UCIs. **Nor will any management fees will be invoiced on this investment by the UCITS and/or other underlying UCI.**

2) Candriam Equities L ESG Market Neutral sub-fund

a. Change of name

In order to identify the quantitative management style of this sub-fund, the Board of Directors has decided to add the work "Edge" to the name of the sub-fund, which will now be as follows: Candriam Equities L ESG Market Neutral Edge.

This change has no impact on how the sub-fund is managed nor on the fees applicable to it.

b. Update of pre-contractual disclosures (PCDs)

To reflect ESMA's guidance on fund names containing terms linked to environmental, social and governance (ESG) or sustainability criteria, the Board of Directors has decided, on the recommendation of the Management Company, to clarify the following question in the PCD of the sub-fund: *What limitations are defined in the investment strategy used to select investments with a view to achieving each of the environmental or social characteristics promoted by this financial product?*

3) Candriam Equities L Oncology Impact sub-fund

To reflect ESMA's guidance on fund names containing terms linked to environmental, social and governance (ESG) or sustainability criteria, the Board of Directors has decided, on the recommendation of the Management Company, to change the name of the sub-fund from Candriam Equities L Oncology Impact to Candriam Equities L Oncology.

This change has no impact on how the sub-fund is managed nor on the fees applicable to it.

These changes will take effect on **05 February 2025**.

The prospectus dated **05 February 2025**, and the key investor information documents will be available free of charge from the registered office of the SICAV or may be accessed free of charge at the following address: <https://www.candriam.lu/en/private/funds-search#>.

The Board of Directors